NCT07276100

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular carcinoma (HCC) whose disease has progressed during prior atezolizumab-bevacizumab therapy. The study will also assess the safety and feasibility of this treatment strategy. Primary Objective: To determine whether FMT can restore or enhance response to atezolizumab and bevacizumab following disease progression. Participants will: Receive a fecal microbiota transplantation (FMT). Resume treatment with atezolizumab and bevacizumab, administered every 3 weeks.

Conditions

• Hepato Cellular Carcinoma (HCC)

Interventions

Type	Name	Description
OTHER	Fecal microbiota transplantation (FMT)	Fecal microbiota transplantation (FMT)
DRUG	Atezolizumab & Bevacizumab	Atezolizumab \& Bevacizumab

Timeline

• Start date: 2026-01-01
• Primary completion: 2027-01-01
• Completion: 2029-01-01
• First posted: 2025-12-10
• Last updated: 2025-12-10

Locations

1 site across 1 country: Italy